Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Optical

Clinical Trials

Presbyopia

More Like This

PR Newswire associated0

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland

Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia

HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting

PR Newswire associated0

HOYA Vision Care Releases One-Year MiYOSMART European Study Results

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

PR Newswire associated0

New Drug Application for "K-911" Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration